0000000001036963
AUTHOR
Cristina Chiriaco
Additional file 7 of A receptor-antibody hybrid hampering MET-driven metastatic spread
Additional file 7: Supplementary Fig. 7. Serum concentration of AbDec-L1 after single i.v. administration to Sprague Dawley rats at different time points.
Additional file 3 of A receptor-antibody hybrid hampering MET-driven metastatic spread
Additional file 3: Supplementary Fig. 3. IVIS images of lungs excised from hHGF-ki mice that received intra-pancreatic injection of HPAF-II cells.
Additional file 2 of hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
Additional file 2.
Additional file 3 of Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy
Additional file 3: Supplement Table 1. MET gene amplification in different cell lines and primary cells derived from human tumors of different origin.
Additional file 6 of A receptor-antibody hybrid hampering MET-driven metastatic spread
Additional file 6: Supplementary Fig. 6. Analysis of CL-901 primary tumors treated with AbDec-L1.
Additional file 2 of A receptor-antibody hybrid hampering MET-driven metastatic spread
Additional file 2: Supplementary Fig. 2. IVIS images of livers excised from hHGF-ki mice that received intra-pancreatic injection of Capan-1 cells.
Additional file 1 of hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
Additional file 1.
Additional file 3 of hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
Additional file 3.
Additional file 5 of A receptor-antibody hybrid hampering MET-driven metastatic spread
Additional file 5: Supplementary Fig. 5. IVIS images of organs excised from hHGF-ki mice that received sub-cuteaneous injection of CL-901 cells.
Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody
The kinase receptor encoded by the Met oncogene is a sensible target for cancer therapy. The chimeric monovalent Fab fragment of the DN30 monoclonal antibody (MvDN30) has an odd mechanism of action, based on cell surface removal of Met via activation of specific plasma membrane proteases. However, the short half-life of the Fab, due to its low molecular weight, is a severe limitation for the deployment in therapy. This issue was addressed by increasing the Fab molecular weight above the glomerular filtration threshold through the duplication of the constant domains, in tandem (DCD-1) or reciprocally swapped (DCD-2). The two newly engineered molecules showed biochemical properties comparable…
Additional file 4 of Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy
Additional file 4: Supplementary Figure 1. Design and binding properties of DO24 single chain antibody fragments. Supplementary Figure 2. Analysis by flow cytometry of cell surface MET expression. Supplementary Figure 3. Quantitative flow cytometer analysis of surface MET levels in A549 wild type, genetically modified, and not transformed human cells. Supplementary Figure 4. Analysis by flow cytometry of cell surface MET expression in carcinoma cells featuring MET overexpression due to high MET gene copy number. Supplementary Figure 5. Analysis of perforin and granzyme B concentrations in the culture supernatants of T cells co-cultured with target cells expressing different surface MET leve…
Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody
The MET oncogene encodes a tyrosine kinase receptor involved in the control of a complex network of biological responses that include protection from apoptosis and stimulation of cell growth during embryogenesis, tissue regeneration, and cancer progression. We previously developed an antagonist antibody (DN30) inducing the physical removal of the receptor from the cell surface and resulting in suppression of the biological responses to MET. In its bivalent form, the antibody displayed a residual agonist activity, due to dimerization of the lingering receptors, and partial activation of the downstream signaling cascade. The balance between the two opposing activities is variable in different…
Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy
Abstract Background Aberrant activation of the MET receptor in cancer is sustained by genetic alterations or, more frequently, by transcriptional upregulations. A fraction of MET-amplified or mutated tumors are sensible to MET targeting agents, but their responsiveness is typically short-lasting, as secondary resistance eventually occurs. Since in the absence of genetic alterations MET is usually not a tumor driver, MET overexpressing tumors are not/poorly responsive to MET targeted therapies. Consequently, the vast majority of tumors exhibiting MET activation still represent an unmet medical need. Methods Here we propose an immunotherapy strategy based on T lymphocytes expressing a Chimeri…
Additional file 4 of A receptor-antibody hybrid hampering MET-driven metastatic spread
Additional file 4: Supplementary Fig. 4. Immunohistochemical analysis of MET phosphorylation in pancreatic primary tumors treated with AbDec-L1.
Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours
BACKGROUND: Interferon-induced expression of programmed cell death ligands (PD-L1/PD-L2) may sustain tumour immuneevasion. Patients featuring MET amplification, a genetic lesion driving transformation, may benefit from anti-MET treatment. We explored if MET-targeted therapy interferes with Interferon-gamma modulation of PD-L1/PD-L2 in MET-amplified tumours.METHODS: PD-L1/PD-L2 expression and signalling pathways downstream of MET or Interferon-gamma were analysed in MET-amplified tumour cell lines and in patient-derived tumour organoids, in basal condition, upon Interferon-gamma stimulation, and after anti-MET therapy.RESULTS: PD-L1 and PD-L2 were upregulated in MET-amplified tumour cells up…
Additional file 1 of A receptor-antibody hybrid hampering MET-driven metastatic spread
Additional file 1: Supplementary Fig. 1. IVIS analysis of primary tumors excised from mice that received intra-pancreatic injections of Capan-1 or HPAF-II pancreatic cancer cells.
A receptor-antibody hybrid hampering MET-driven metastatic spread
AbstractBackgroundThe receptor encoded by the MET oncogene and its ligand Hepatocyte Growth Factor (HGF) are at the core of the invasive-metastatic behavior. In a number of instances genetic alterations result in ligand-independent onset of malignancy (METaddiction). More frequently, ligand stimulation of wild-type MET contributes to progression toward metastasis (METexpedience). Thus, while MET inhibitors alone are effective in the first case, combination therapy with ligand inhibitors is required in the second condition.MethodsIn this paper, we generated hybrid molecules gathering HGF and MET inhibitory properties. This has been achieved by ‘head-to-tail’ or ‘tail-to-head’ fusion of a sin…
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
Abstract Background The tyrosine kinase receptor encoded by the MET oncogene is a major player in cancer. When MET is responsible for the onset and progression of the transformed phenotype (MET-addicted cancers), an efficient block of its oncogenic activation results in potent tumor growth inhibition. Methods Here we describe a molecular engineered MET antibody (hOA-DN30) and validate its pharmacological activity in MET-addicted cancer models in vitro and in vivo. Pharmacokinetics and safety profile in non-human primates have also been assessed. Results hOA-DN30 efficiently impaired MET activation and the intracellular signalling cascade by dose and time dependent removal of the receptor fr…